公开(公告)号：EP3154537A4

公开(公告)日：2017-12-27

申请号：EP15806506

申请日：2015-06-11

申请人： MERCK SHARP & DOHME

发明人： LEAVITT KENNETH ,  CROWLEY BRENDAN ,  BELL IAN M ,  HARVEY ANDREW ,  AVERY THOMAS ,  PAUL DHARAM ,  RIPPER JUSTIN ,  HUFF BELINDA ,  SINGH RAJINDER ,  SCHAEFFER LAURENT ,  JOSEPH CHRISTOPHE ,  MORICE CHRISTOPHE ,  GIETHLEN BRUNO ,  BAZZINI PATRICK ,  FROMEYER AURELIE

IPC分类号： C07C311/08 ,  A61K31/18 ,  A61P25/28 ,  C07C311/37 ,  C07D213/64 ,  C07D213/69 ,  C07D239/34

CPC分类号： C07C311/29 ,  C07C307/10 ,  C07C311/08 ,  C07C323/67 ,  C07C2601/02 ,  C07C2602/50 ,  C07D213/64 ,  C07D213/65 ,  C07D213/69 ,  C07D239/34

摘要： Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein "RIa", "RIb", "RIc", "RId", "RIe", are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

公开(公告)号：EP2888005A4

公开(公告)日：2016-04-20

申请号：EP13830277

申请日：2013-08-19

申请人： MERCK SHARP & DOHME

发明人： APGAR JAMES M ,  ARASAPPAN ASHOK ,  BIFTU TESFAYE ,  CHEN PING ,  FENG DANQING ,  GUIDRY ERIN ,  HICKS JACQUELINE ,  KEKEC AHMET ,  LEAVITT KENNETH ,  LI BING ,  MCCRACKEN TROY ,  SEBHAT IYASSU ,  QIAN XIAOXIA ,  WEI LAN ,  WILKENING ROBERT ,  WU ZHICAI

IPC分类号： C07D519/00 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/454 ,  A61P3/10

CPC分类号： C07D519/00 ,  A61K31/366 ,  A61K31/397 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  A61K2300/00

摘要： Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.